Literature DB >> 2852604

Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables.

A Eklund1, O Eriksson, L Håkansson, K Larsson, K Ohlsson, P Venge, H Bergstrand, A Björnson, R Brattsand, C Glennow.   

Abstract

Bronchoalveolar lavage (BAL) was performed on eleven healthy smokers before and after eight weeks of oral treatment with N-acetylcysteine (NAC) 200 mg t.i.d. The concentrations of selected eosinophil and neutrophil granule constituents and of selected proteases and protease inhibitors, albumin and endotoxin were determined in the recovered BAL fluid and in plasma or serum samples. In addition, in vitro chemotactic activities for neutrophils and eosinophils were assessed in the BAL fluid. Significant reductions in BAL fluid content of lactoferrin (LF), eosinophil cationic protein (ECP), antichymotrypsin (ACT) and chemotactic activity for neutrophils were recorded after NAC treatment. The levels of other examined markers tended to be reduced or were not affected. In serum/plasma, the concentrations of myeloperoxidase (MPO) and elastase were reduced after NAC treatment whereas concentrations of other constituents examined were unaltered. These data, together with previously reported findings, suggest that oral NAC may influence the activity of "inflammatory" cells in the bronchoalveolar space of smokers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852604

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

1.  Lactoferrin and secretory IgA in the bronchoalveolar lavage fluid from patients with a stable asthma.

Authors:  E A van de Graaf; T A Out; A Kobesen; H M Jansen
Journal:  Lung       Date:  1991       Impact factor: 2.584

2.  N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid.

Authors:  W A De Backer; B Amsel; P G Jorens; L Bossaert; P S Hiemstra; P van Noort; F J van Overveld
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

3.  N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients.

Authors:  Shresh Pathak; Corey Stern; Andrea Vambutas
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

4.  Effect of N-acetyl cysteine on thiol levels.

Authors:  P N Dekhuijzen; C L Van Herwaarden
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

Review 5.  Alcohol abuse and pulmonary disease.

Authors:  Darren M Boé; R William Vandivier; Ellen L Burnham; Marc Moss
Journal:  J Leukoc Biol       Date:  2009-07-14       Impact factor: 4.962

6.  Use of methyl prednisolone and antioxidants in mercuric chloride-induced experimental vasculitis.

Authors:  F J Qasim; P W Mathieson; S Thiru; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

Review 7.  Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.

Authors:  Hoi Nam Tse; Cee Zhung Steven Tseng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-08-06

Review 8.  Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.

Authors:  Xixin Yan; Yuanlin Song; Ce Shen; Wenbing Xu; Liangan Chen; Jian Zhang; Huiguo Liu; Mao Huang; Guoxiang Lai; Guishen Qian; Jing Wang; Xianwei Ye; Jinping Zheng; Chunxue Bai
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-22

9.  Response.

Authors:  Hoi Nam Tse; Luca Raiteri; King Ying Wong; Lai Yun Ng; Kwok Sang Yee
Journal:  Chest       Date:  2014-01       Impact factor: 9.410

Review 10.  The role for N-acetylcysteine in the management of COPD.

Authors:  P N R Dekhuijzen; W J C van Beurden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.